Coeptis Therapeutics Holdings, Inc. (COEP)
- Previous Close
0.2877 - Open
0.2950 - Bid --
- Ask --
- Day's Range
0.2659 - 0.2950 - 52 Week Range
0.2550 - 2.1000 - Volume
265,105 - Avg. Volume
516,013 - Market Cap (intraday)
10.145M - Beta (5Y Monthly) -0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
coeptistx.comRecent News: COEP
Performance Overview: COEP
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COEP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COEP
Valuation Measures
Market Cap
10.68M
Enterprise Value
12.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.45
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-168.04%
Return on Equity (ttm)
-485.13%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-21.27M
Diluted EPS (ttm)
-0.5100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.47M
Total Debt/Equity (mrq)
28.38%
Levered Free Cash Flow (ttm)
-6.92M